Certolizumab Pegol

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Cimzia; Belgium: Cimzia; Bulgaria: Cimzia; Czech Republic: Certolizumab pegol, Cimzia; Denmark: Cimzia; Estonia: Cimzia; Finland: Cimzia; France: Cimzia; Germany: Cimzia; Greece: Cimzia; Hungary: Cimzia; Ireland: Cimzia; Latvia: Cimzia; Lithuania: Cimzia; Luxembourg: Cimzia; Malta: Cimzia; Netherlands: Cimzia; Poland: Cimzia; Portugal: Cimzia; Romania: Cimzia; Slovakia: Cimzia; Slovenia: Cimzia; Spain: Cimzia; Sweden: Cimzia; UK: Cimzia.

North America

Canada: Cimzia; USA: Cimzia.

Drug combinations


Certolizumab Pegol: C~2115~H~3252~N~556~O~673~S~16~ (peptide). Mw: 91 kDa. Immunoglobulin, anti-(human tumor necrosis factor α) Fab’ fragment (human-mouse monoclonal CDP870 heavy chain), disulfide with human-mouse monoclonal CDP870 light chain, pegylated at Cys-221. The Fab’ fragment is composed of a light chain with 214 amino acids and a heavy chain with 229 aa. CAS: 428863-50-7.

Pharmacologic Category

Miscellaneous Therapeutic Agents; Biologic Response Modifiers, Disease-modifying Antirheumatic Drugs. Immunomodulator, TNF blocker. (ATC-Code: L04AB05).

Mechanism of action

Certolizumab pegol binds to TNFα, inhibiting its role as a key mediator of inflammation. Elevated levels of TNFα have been implicated in the pathology of Crohn’s disease and rheumatoid arthritis. TNFα is strongly expressed in the bowel wall in areas involved by Crohn’s disease and fecal concentrations of TNFα in patients with Crohn’s disease have been shown to reflect clinical severity of the disease. After treatment with certolizumab pegol, patients with Crohn’s disease demonstrated a decrease in the levels of C-reactive protein (CRP). Increased TNFα levels are found in the synovial fluid of rheumatoid arthritis patients and play an important role in the joint destruction that is a hallmark of this disease. Does not contain a fragment crystallizable (Fc) region, which is normally present in a complete antibody, and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro. Certolizumab pegol showed no reactivity with a designated standard panel of normal human tissues.

Therapeutic use

Indicated for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Treatment of adults with moderately to severely active rheumatoid arthritis.

Pregnancy and lactiation implications

Should be used during pregnancy only if clearly needed. Not recommended during lactation.

Unlabeled use


None known to date.

Warnings and precautions

Increased risk of serious infections; if an infection becomes serious, treatment should be stopped. Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers. Hepatitis B virus (HBV) reactivation may occur in HBV carriers during and several months after therapy; if reactivation occurs, treatment should be stopped. If symptoms of cytopenias or pancytopenia develop, stopping the drug should be considered. Treatment should also be stopped if Lupus-like syndrome develops. Heart failure, worsening or new onset, anaphylaxis or serious allergic reactions and demyelinating disease, exacerbation or new onset, may occur.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart